Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of Somatic Mutations on Treatment Response and Resistance in Chronic Myeloid Leukemia.

International journal of laboratory hematology - 1 Oct 2026

Mishra Shruti, Kumar Kailash, Kumar Dinesh, Kamak Ashwin, Singh Lovely, Kumar Nilesh

Abstract excerpt

INTRODUCTION: Tyrosine kinase inhibitors (TKIs) have transformed the treatment of chronic myeloid leukemia (CML); yet, diverse molecular responses and resistance persist. BCR::ABL1 kinase-domain (TKD) mutations constitute just a fraction of this resistance, and the impact of additional somatic mutations on disease progression and early molecular response remains incompletely defined. METHODS: This single-centre...

Read the complete abstract on PubMed

Topics

Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Drug Resistance, Neoplasm
Mutation
Female
Protein Kinase Inhibitors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Male

Fusion Proteins, bcr-abl

Middle Aged

Adult

High-Throughput Nucleotide Sequencing

Aged

Treatment Outcome

Cohort Studies

Source

Open in PubMed Open full text

Identifiers

PMID: 42252205
DOI: 10.1111/ijlh.70165
PMCID: PMC13555106

Genes

ABL1
BCR
ASXL1
ELN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of Somatic Mutations on Treatment Response and Resistance in Chronic Myeloid Leukemia.PMID 42252205Read ↗

MUTATIONAL STATUS AND TREATMENT EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.Semantic proximity Read ↗

Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study.Semantic proximity Read ↗

Prevalence and Prognostic Impact of ASXL1 Somatic Mutation in Patients with Chronic Myeloid Leukemia: A Systemic Review and Meta-AnalysisSemantic proximity Read ↗

Clinical Significance of the S348l Mutation in BCR-ABL as a Dominant Variant in Indonesian CML Patients Under Tyrosine Kinase Inhibitor Therapy: A Cohort Study.Semantic proximity Read ↗

Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia.Semantic proximity Read ↗

Somatic Mutations and Outcomes in CML Adolescent and Young Adults Compared to Children, Adults, and BCR::ABL1-positive ALL PatientsSemantic proximity Read ↗

Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Genetic landscape of chronic myeloid leukemia.Semantic proximity Read ↗

Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study.Semantic proximity Read ↗

Beyond BCR::ABL1—The Role of Genomic Analyses in the Management of CMLSemantic proximity Read ↗

Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapySemantic proximity Read ↗

Resistance mutations in CML and how we approach them.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.